Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation

Table 2

Univariate analysis of the correlation between demographic and clinicopathological characteristics and survival time in patients with MM.

Characteristics			OS (mean)	PFS (mean)
Age	≥60	100	20.355	16.595
	<60	81	28.233	20.102
Gender	Male	114	23.614	18.322
	Female	67	24.333	17.897
Ig isotype	IgG	97	22.531	16.210
	IgA	47	24.419	19.674
	Light chain	31	21.914	18.971
	Others	6	51.645	33.772
ISS staging	I	31	29.096	22.806
	II	86	28.490	21.231
	III	64	15.161	11.796
ECOG	0-1	153	25.098	18.830
	2–4	28	17.230	14.531
Plt (×10^9/L)	≥100	156	25.251	19.403
	<100	25	15.327	10.440
Hb (g/L)	≥100	55	22.732	21.187
	<100	126	26.511	16.846
Scr (μmol/L)	≥177	39	13.888	10.382
	<177	142	26.625	20.302
Serum Alb (g/L)	≥35	49	25.292	20.049
	<35	132	23.357	17.465
Serum -MG (μmol/L)	≥5.5	64	15.161	11.796
	<5.5	117	28.650	21.648
Serum LDH (IU/L)	≥245	28	18.717	14.700
	<245	153	24.826	18.799
Serum Ca (mmol/L)	≥2.75	21	13.268	11.910
	<2.75	160	25.273	18.986
Bortezomib	Yes	111	24.816	18.957
	No	70	22.398	16.909
Thalidomide	Yes	144	26.712	20.368
	No	37	12.860	9.590
Blood transfusion	Yes	68	22.376	14.998
	No	113	24.786	20.070